Over the past 15 years, my clinical activity has focused on thoracic, HBP, GU malignancies and NET. My preclinical and translational research activity has focused on targeting signal transduction (particularly the MAPK and PI3K pathways) as a therapeutic strategy in solid tumors and leukemias, as well as drug/biomarker co-development.